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Abstract
Background: Retinol Binding Protein 4 (RBP4) is an exciting new biomarker for the determination of insulin resistance and
type 2 diabetes. It is known that circulating RBP4 resides in multiple variants which may provide enhanced clinical utility,
but conventional immunoassay methods are blind to such differences. A Mass Spectrometric immunoassay (MSIA)
technology that can quantitate total RBP4 as well as individual isoforms may provide an enhanced analysis for this
biomarker.
Methods: RBP4 was isolated and detected from 0.5 uL of human plasma using MSIA technology, for the simultaneous
quantification and differentiation of endogenous human RBP4 and its variants.
Results: The linear range of the assay was 7.81–500 ug/mL, and the limit of detection and limit of quantification were
3.36 ug/mL and 6.52 ug/mL, respectively. The intra-assay CVs were determined to be 5.1% and the inter-assay CVs were
9.6%. The percent recovery of the RBP4-MSIA ranged from 95 – 105%. Method comparison of the RBP4 MSIA vs the Immun
Diagnostik ELISA yielded a Passing & Bablok fit of MSIA =1.056ELISA – 3.09, while the Cusum linearity p-value was .0.1
and the mean bias determined by the Altman Bland test was 1.2%.
Conclusion: The novel RBP4 MSIA provided a fast, accurate and precise quantitative protein measurement as compared to
the standard commercially available ELISA. Moreover, this method also allowed for the detection of RBP4 variants that are
present in each sample, which may in the future provide a new dimension in the clinical utility of this biomarker.
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Introduction
The evolution of proteomics over the past decade has seen it
mature from its nebulous and esoteric origins into a facet of
science with a tangible objective; to develop and apply targeted
mass spectrometric assays for the analysis of human proteins [1].
Even though this has lead to the introduction of numerous
approaches to address this basic theme, practitioners universally
agree that the translation into clinical (Clinical Proteomics) is the
next rational step. However, the legitimization of proteomics as a
clinical approach is not a trivial procedure since the current
standard in protein analytics is the enzyme linked immunosorbent
assay (ELISA), a robust and reliable quantitative approach that
has an established record that spans more than 30 years [2,3].
The majority of these nouveau technologies that are competing
for clinical acceptance are based on the fundamental principle of
the ELISA; immuno-affinity recognition and capture of a target
for subsequent quantitative detection. However, the adaptation of
these approaches to incorporate mass spectrometry (MS) for
detection has been at the very least challenging, largely due to the
polarized philosophies regarding the application of MS. The
majority of these technologies subscribe to a bottom-up approach;
in which the proteins are proteolytically digested, (either globally
or post affinity purification) for subsequent surrogate peptide
detection [4,5]. Even though proteomics practitioners are
accustomed to bottom-up methodologies; the digestion process
results in increased cost, increased run time and grossly increased
sample complexity as compared to classical ELISA.
Other assay features that need to be considered are the general
performance characteristics of the ELISA that have been
repeatedly demonstrated over the course of its existence. Only
very recently have potential clinical proteomics approaches begun
to address this issue, by benchmarking the characteristics of their
MS based assay against available ELISA for the same target [6].
However, the approach demonstrated used a bottom-up format
and suffered from the same shortcomings as other assays of this
nature.
The simplest remedy to this issue is to adopt a top-down
approach, which differs from bottom-up in that the intact protein
target is detected instead of a surrogate peptide. Since this
alternative proteomic philosophy omits proteolytic digestion, top-
down assays are comparatively simpler, much faster and less
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17282expensive. Moreover, this approach has the unique ability to both
qualitatively and quantitatively evaluate mass shifted variants in a
single analysis. Neither bottom-up proteomic approaches nor
classical ELISA possess this capability. This ability to detect
protein micro-heterogeneity has only very recently become a topic
of discussion within proteomics [7,8], but in practice has shown
strong clinical potential [9,10].
Presented is a unique top-down proteomic method for the
analysis of Retinol Binding Protein 4 (RBP4), a clinically
significant biomarker for the detection of insulin resistance and
type 2 diabetes [11]. This protein is also known to exhibit micro-
heterogeneity [7,12,13,14,15] in both human plasma and urine,
however the study of this phenomena for potentially enhanced
clinical utility is lacking. Described is a MS immunoassay method
for the analysis of RBP4, which utilizes a novel approach to
protein quantitation that is based on MS signal normalization with
a generic exogenous protein.
Not only does this novel assay provide Total RBP4 concentra-
tion measurements, but individual values of protein variants that
are found within human plasma samples. This unique approach to
MS quantification forgoes the need to generate costly isotopically
labeled peptides, and its generic nature can serve as a template for
the quantitation of other protein targets. Moreover, the utility of
this quantitative approach allows for the expedited development of
cost effective MS assays. This RBP4 assay described was fully
characterized and its quantitative performance was benchmarked
against a commercially available ELISA.
Materials and Methods
Approach
The novel proteomic method described for the targeted analysis
of RBP4 utilized the MSIA approach; immuno-affinity protein
enrichment and capture followed by mass spectrometric (MS)
detection of the eluted protein target. This approach has been
previously utilized in the analysis of numerous proteins from a
variety of different biological matrices. As described here, the front
end sample processing is configured as an affinity pipette tip
(MSIA-Tip) [16,17,18,19], which allows for the rapid and highly
efficient retrieval of the RBP4 from a biological matrix. On the
back end, MALDI-TOF MS detection provides quantitative and
qualitative data of the intact protein. This approach to top-down
proteomics is ideal for RBP4 analysis since it is a heterogeneous
biomarker and all variant forms are detected and quantified in a
single analysis.
Reagents
The MSIA-Tips were provided by Intrinsic Bioprobes Inc. The
antibodies used in the MSIA technology were polyclonal anti-
RBP4 from Dako and polyclonal anti-beta-lactoglobulin pur-
chased from GeneTex
H, Inc. The polypropylene 96-micro titer
plates (deep well and standard) used were from Greiner Bio-One.
Premade 10 mM HEPES-buffered saline with 3 mM EDTA and
0.005% (vol/vol) polysorbate 20 (HBS-EP) used was provided by
Biacore while purified human urinary RBP4 standard (huRBP4),
bovine beta-lactoglobulin standard (b-Lac), tween 20, sinapic acid
and all other chemical reagents were obtained from Sigma-
Aldrich. The reference RBP4 ELISA was purchased was the
Immun Diagnostik RBP4 ELISA kit from ALPCO.
Samples
All samples used in this study were purchased from PromedDx
(Norton, MA). Heparinized plasmas from a total of 45 individuals
were obtained and arrived de-identified as to ensure the privacy
and protection of the individuals who provided samples. Five
samples were used for the method characterization studies, while
the remaining 40 were used in the method comparison. The
samples consisted of a mixture of controls (n=7, 3 males and 4
females; mean age 63) and individuals diagnosed with acute
myocardial infarction (n=33, 17 males and 16 females; mean age
73). Ethnicity information regarding the samples was unavailable.
Samples were stored frozen at 280uC until ready for use.
Calibrator and Plasma Sample Preparation
The RBP4-MSIA method utilized a seven point calibration
curve and a single control point. Calibrants were prepared by
diluting the purified huRBP4 in HBS-EP buffer so that the
adjusted concentrations used (accounting for the sample dilution
factor) ranged from 7.81 to 500 ug/mL. The control sample was
prepared in the same fashion as calibrants but at a concentration
of 100 ug/mL. In the standard runs, plasma samples were serially
diluted 1:100 in HBS-EP buffer and a 50 uL aliquot was then used
in each analytical sample, however, this sample volume was varied
during the linearity determination (described accordingly below).
The bovine b-Lac, which is utilized as the internal reference
standard (IRS) for assay quantitation, was prepared by serially
diluting a 1 mg/mL stock solution in HBS-EP to a final
concentration of 25 ug/mL. The selection of the IRS as bovine
b-Lac was based on several criteria that included reagent (antibody
and antigen) cost and availability, mass spectrometric utility
(sufficiently ionize and produce an m/z that does not interfere with
target analyte), as well as the fact it is exogenous to human plasma.
These factors made bovine b-Lac as an ideal IRS for this
quantitative RBP4 assay. The analytical samples were then
prepared by aliquoting sample (diluted plasma or standard) into
individual wells of a 96-deep well micro titer plate already
containing a 50 uL aliquot of the IRS (this amount of IRS was
empirically determined to saturate its capture antibody, data not
shown). All samples were then diluted to 1 mL with sample diluent
(HBS-EP that contains 0.1% tween 20).
Work Flow of the Mass Spectrometric Immunoassay
The MSIA-Tips utilized here were prepared using standard
protocols as previously described [18,20], but tailored with a
RBP4/beta-lactoglobulin antibody ratio of 16.4:1 (wt/wt), respec-
tively. This ratio was experimentally determined to produce
optimum results (data not shown). The method was performed
with the aid of a Beckman Multimek 96 pipetting workstation,
allowing up to 96 analyses to be performed at once. The repetitive
pipetting action of the workstation (aspirating and dispensing) is
capitalized on in every step in the assay. This work flow of the
assay is illustrated in Fig. 1A which includes: 1) incubation for the
simultaneous capture and enrichment of both the target protein
and the IRS from the sample (200 repetitions, 100 uL per), 2) tip
washing with HBS-EP and then two waters (20 repetitions of
100 uL for each), 3) protein elution and 4) target analyte analysis
(qualitative and quantitative) by MALDI-TOF MS. The protein
elution from the MSIA-Tips was performed in parallel by drawing
7 uL of MALDI matrix solution [an aqueous solution of sinapic
acid (13.3 g/L, 33% (vol/vol) acetonitrile, and 0.4% (vol/vol)
trifluoroacetic acid] in the pipettes and depositing the protein
matrix mix directly onto a MALDI-TOF MS target [18]. This
entire process was applied to both the standard (curve and control)
and the plasma samples. Experiments were performed to
empirically determine an optimum assay and elution procedure
(data not shown). Mass spectrometric analysis of the intact proteins
was performed using a Bruker linear Autoflex MALDI-TOF in
delayed extraction, positive ion mode. MS settings used were a
Mass Spectrometry RBP4 Immunoassay
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17282Figure 1. Describes the MSIA workflow and provides examples of the normalized quantitative MS responses. A) Work flow for the
quantitative analysis of RBP4 from human plasma by MSIA. B) Selected quantitative MS responses of the RBP4 MSIA.
doi:10.1371/journal.pone.0017282.g001
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1.45 kV, a 9.50 kV lens, a 670 ns delay and a 2 GS/s sample
rate. Each spectrum generated consisted of the sum of three, 500
shot signal acquisitions. This MS sampling amount was empiri-
cally determined to product a spectrum that was representative a
given sample for accurate target quantification. Each spectrum
underwent single point internal calibrations with the IRS signal (b-
Lac
+1 =18,278.2). Calibrated spectra were then processed and
normalized to the integral of the IRS signal in each spectrum.
Quantitative aspect of the RBP4 MSIA is shown in Fig. 1B, in
which shows an overlay of normalized MS traces that were
obtained from calibrant samples with varying concentrations of
huRBP4 standard. Since sinapic acid (SA) was used as the MALDI
matrix, SA adducts observed in higher concentration samples
which may produce some matrix effect bias. Integrals for all RBP4
forms present in each sample were then obtained and recorded.
The quantitation of endogenous retinol binding protein 4 was
achieved by summing the integrals of all RBP4 forms observed
within each sample. This summed or total integral is then applied
to the established line equation generated by the calibrants within
each run. The resulting concentration is for the total amount of
RBP4 present in each sample. The total RBP4 concentration was
used in the studies to determine the performance characteristics of
the assay.
Assay Characterization Studies
We performed a series of studies to characterize the perfor-
mance of the RBP4 MSIA and determine the standard
specifications for clinically applied immunoassays. The reproduc-
ibility of the assay was determined by comparing MSIA results of
standard curves over an eleven day period (Fig. 2). The intra- and
inter-assay imprecision was determined by analyzing replicates of
three different stock plasma samples over the same eleven day
period.
Prior to these studies, assay development included the
establishment of the limit of detection (LOD) and the limit of
quantification (LOQ). The LOD was defined as 3 SD of the lowest
normalized back ground signal obtained from blank samples,
while the LOQ was delineated as the lowest concentration of
Figure 2. Shows plots of RBP4 control and calibrator samples analyzed by MSIA. Samples ranged in concentration from 7.06 to 500 ug/mL
(0.30 to 24.31 nmol/mL) and the data represents the results obtained over an eleven day period.
doi:10.1371/journal.pone.0017282.g002
Figure 3. Are the plotted results of the quantitative MSIA
linearity study. The regression analysis was only able to fit a first
order polynomial (1.087+3.10166;R
2=0.990) to the data set. The
absence of non-linearity describes the assay as possessing linear
characteristics.
doi:10.1371/journal.pone.0017282.g003
Table 1. Results of the percent recovery study.
No Spike Low Spike Medium Spike High Spike
Sample (0 ug/mL) (35 ug/mL) (150 ug/mL) (350 ug/mL)
Dilutent
Control
0 35.07 152.91 323.23
Sample 1 28.42 33.41 156.20 329.01
Sample 2 16.97 32.70 143.99 338.64
Sample 3 31.15 33.85 145.29 349.67
% Mean
Recovery
N.A. 95.03 97.11 104.91
(+/2 S.D.) 1.66 4.39 3.20
doi:10.1371/journal.pone.0017282.t001
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CV,10%. The LOD and LOQ were calculated by repeatedly
analyzing standard replicates over a period of 3 months.
Precision of the assay was also evaluated by the linearity of
dilution. This was assessed by running MSIA on serially diluted
plasma samples. The dilution consisted of taking a high RBP4
concentration sample and diluting with increasing proportions of a
plasma sample with a low RBP4 concentration (100, 50, 33.3, 25,
16.65, 12.5 and 6.25% contribution of the high sample).
Preliminary RBP4 concentrations were determined by ELISA.
Each dilution was prepared in quadruplicate and the RBP4
concentration in each was determined by MSIA. The assay
linearity was evaluated by performing a polynomial regression
(least-squares regression using polynomials with various orders) to
determine the degree of non-linearity of the set. The acceptable
level of non-linearity was selected to be ,10% (Fig. 3).
Figure 4. Is a comparison between quantitative MSIA and the Immun Diagnostik ELISA for RBP4. A) RBP4 concentrations (ug/mL)
obtained by both methods were compared by same-scale Passing & Bablok regression (solid black line). The dashed lines are the 95% confidence
interval. B) The Altman-Bland test determined that the overall bias of the MSIA to be 1.195 (solid black line). The dashed lines represent the 95% limit
of agreement.
doi:10.1371/journal.pone.0017282.g004
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accuracy of quantification. This was run on three different plasma
samples that were established, by ELISA, as having low endogenous
RBP4 concentrations. Sample aliquots were either prepared neat or
underwent standard addition with three increasing concentration
levels of RBP4 standard (35, 150 and 350 ug/mL). RBP4
measurements were taken by MSIA and the percent recovery
between the expected and the measured was calculated and
averaged foreachconcentrationlevel.Theseresultsarepresentedin
Table 1, in which the results of each spiked measurement after the
endogenous amount of RBP4 had been subtracted out, are
displayed for each concentration level in all three samples.
Method Comparison
The RBP4 MSIA was referenced to the Immun Diagnostik
RBP4 ELISA. A total of 40 plasma samples were utilized in this
study with endogenous RBP4 concentrations between 6.7 ug/mL
and 182.9 ug/mL as determined by the Immun Diagnostik RBP4
ELISA in a preliminary screening. The RBP4 MSIA method and
the ELISA reference studies (also performed by the Immun
Diagnostik RBP4 ELISA kit) were performed on the same day.
The ELISA analyses were performed according to the instructions
provided by the manufacturer (a standard sandwich assay format
with horse radish peroxidase conversion of 3,39, 5,5"-tetramethyl-
benzidine substrate for detection) and the absorbance readings
were taken on Cary 50 UV/Vis spectrophotometer (Varian).
Calculations and Statistics
Data were analyzed using Microsoft Excel 2003 and Analyse-itH
(Analyse-it Software).
Results
Performance Specifications of the Msia
The application of MSIA for RBP4 analysis was consistently
able to detect the target as well as produce spectra that
distinguished between samples containing different concentrations
of RBP4. The internal calibration of each mass spectrum by the
IRS produced intact RBP4 m/z values that had a mass accuracy
within 0.014% (,150 ppm). The average resolution observed
during these studies was ,900 (FWHM), which is more than
adequate to resolve the signals produced by the known variants of
RBP4. Combined with the immuno-affinity capture, this was
sufficient for confirmation of the identity of the detected analyte.
The calibrator standard concentrations of RBP4 ranged from
7.81 to 500 ug/mL (0.38 to 24.31 nmol/mL). The developed
calibration curves were linear throughout the established range,
demonstrating a R
2=0.996, intercept =0.523 and a slope
=0.996 (Fig. 2). Analyses of control samples, with a theoretical
concentration of 100 mg/L (4.86 nmol/mL), were also performed
and demonstrated an average analytical error of , 61.0%. The
intra- and inter-day CVs were determined to be 5.1 and 9.6%,
respectively. The LOD was experimentally determined to be
3.36 ug/mL (0.16 nmol/mL), while the LOQ was 6.52 ug/mL
(0.31 nmol/mL). The lowest point of curve was determined to be
7.81 ug/mL (0.38 nmol/mL) which was selected for simplicity
(due to the serial dilutions used) in preparing the calibrants.
Fig. 3 shows the linearity of the assay as determined by polynomial
regression with an allowable non-linear tolerance of ,10%. The
MSIA data points generated wereonly able tobe fitted by afirstorder
polynomial with an R
2=0.990. Since the non-linearity tolerance is
satisfied, the assay exhibits linear characteristics confirming that the
sample matrix does not influence the analysis at lower analyte
concentrations.The percent recovery studies demonstrated that there
was no observable sample matrix interference at the three spiked
RBP4 concentration levels (35, 150 and 350 ug/mL) in the test
plasma samples. As shown in Table 1, the Mean Recovery ranged
between 95 – 105% while exhibiting nominal deviation.
Method Comparison
The RBP4 MSIA quantitative values were referenced to the
Immun Diagnostik immunoassay results for the 40 plasma samples
Figure 5. Shows representative MS traces of RBP4 acquired during the method comparison study. The normalized mass spectra display
a wide variety of RBP4 variation found in human plasma.
doi:10.1371/journal.pone.0017282.g005
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(0.318 umol/L to 8.68 umol/L). In the ELISA measurements,
two samples had results that were above the range of the assay, so
they were repeated. The repeat analyses were performed using a
2-fold dilution of the sample and the measured concentration was
doubled to account for the dilution. The repeats confirmed that
these samples had the two highest RBP4 concentrations and the
repeat values were integrated into the data set. All other
measurements were performed in a single determination.
The same samples were then analyzed for RBP4 by MSIA (also
in duplicate). The MSIA quantitation showed two samples as
having RBP4 values that were below the establish LOQ, therefore
were repeated but with a 2-fold increase in the amount of plasma
sample used. The measured RBP4 concentrations were then
mathematically corrected by dividing by 2. The MSIA repeats
confirmed the low concentration of RBP4 in these two samples,
therefore the repeat RBP4 measurements were integrated into the
data set. All other MSIA measurements were acquired in a single
run.
The method comparison was performed by referencing the
MSIA RBP4 concentrations to the ELISA measurements. These
values were plotted and a Passing & Bablok regression was applied
[21]. This same-scale plot is shown in Fig. 4A, which yielded a
Passing & Bablok fit of; MSIA=1.056 ELISA – 3.09, and a
Cusum linearity p-value .0.1. The Altman Bland test was also
applied to the data set and calculated the bias to be 1.2% (Fig. 4B).
The MSIA approach to protein analytics also allows for the
detection and identification of protein heterogeneity (variants)
based on changes in their molecular weights. The intact protein
MS results demonstrated that gross heterogeneity in endogenous
RBP4 was present in the samples analyzed. This is illustrated in
Fig. 5, in which several representative mass spectra are shown
displaying the variety of in the protein target profiles. Qualitative
variation of plasma RBP4 has been previously described and
characterized [7,12,13,14,15] using a variety of protein analytical
techniques. Using MS detection, this translates into the observa-
tion of Parent RBP4
+1 (m/z =21,066.5), des-L RBP4
+1
(MW=20,953.4) and des-LL RBP4
+1 (MW=20,840.4) being
routinely reported. Some samples include minor forms of RBP4
that have been less notably observed in human plasma [7]; being
the des-SERNLL RBP4
+1 (m/z=20,353.7 and des-RNLL
RBP4
+1 (m/z=20,569.9). The data generated from this sample
population used in the method comparison study again confirmed
the presence of these same species in varying degrees of abundance
in some samples.
RBP4 Variant Quantification
The ability of this approach to detect RBP4 variants is not solely
qualitative. Since the determination of the total RBP4 concentra-
tion included the contribution of all RBP4 species detected in each
sample, each variant can also be quantitatively segregated. This
was achieved by determining the percent contribution of each
variant to the total integral in each sample. This fraction was then
applied to the sample total RBP4 concentration to calculate the
concentration of the each specific variant within each. A list of the
RBP4 variant concentrations are presented in Table 2.
Discussion
This top-down approach to immuno-affinity mass spectrometry
clearly demonstrated that it has the ability to rapidly quantify
RBP4 from human plasma over a wide range of concentrations.
The described approach to protein quantitation, based on the use
of an exogenous IRS that is co-extracted by a multiplexed
antibody system, has been previously discussed [22,23], however,
this is the first report of such an approach in the quantitative
measurement of RBP4. The developed assay performed with a
high degree of analytical specificity covering a range of 7.81 to
500 ug/mL (0.38–24.31 nmol/mL), which exceeds the dynamic
range of many current commercial RBP4 ELISA kits. The
Table 2. RBP4 variant concentrations determined by MSIA.
Average Concentration (ug/
mL)
Sample
RBP4-
parent des-L des-LL des-RNLL des-SERNLL Total
1 22.30 2.20 0.00 0.00 0.00 24.50
2 53.18 13.83 0.00 0.00 0.00 67.01
3 29.12 2.92 0.00 0.00 0.00 32.03
4 22.47 4.39 0.00 0.00 0.00 26.87
5 1.58 0.32 0.00 0.00 0.00 1.89
6 48.54 17.27 0.00 0.00 0.00 65.80
7 2.75 1.85 10.62 2.51 0.00 17.74
8 15.26 23.19 49.59 4.49 0.00 92.53
9 54.53 73.28 24.59 2.46 1.35 156.21
10 20.53 7.14 1.33 0.00 0.00 29.00
11 20.78 0.00 0.00 0.00 0.00 20.78
12 43.63 12.64 1.66 0.00 0.00 57.93
13 12.67 3.19 0.00 0.00 0.00 15.86
14 8.33 2.63 0.00 0.00 0.00 10.96
15 20.50 13.70 1.79 0.00 0.00 35.99
16 24.51 45.80 45.28 3.25 0.00 118.84
17 49.21 23.98 5.04 0.00 0.00 78.22
18 55.21 17.76 2.72 0.00 0.00 75.69
19 15.74 7.76 0.00 0.00 0.00 23.50
20 22.33 29.38 24.76 1.79 1.34 79.60
21 26.42 17.00 4.62 1.37 1.67 51.08
22 48.71 26.32 3.98 1.76 1.58 82.34
23 17.44 6.59 0.00 0.00 0.00 24.03
24 15.51 28.12 9.03 2.61 3.54 58.81
25 18.88 0.00 0.00 0.00 0.00 18.88
26 23.46 4.84 0.00 0.00 0.00 28.30
27 20.27 4.24 0.00 0.00 0.00 24.51
28 30.51 65.81 83.99 3.98 0.00 184.29
29 32.77 34.19 16.29 0.00 0.00 83.25
30 41.16 48.90 27.04 0.00 0.00 117.09
31 39.59 28.26 5.80 1.25 0.00 74.90
32 29.57 28.49 94.79 12.88 1.10 166.83
33 31.33 40.11 27.08 3.00 0.00 101.52
34 19.57 4.52 0.00 0.00 0.00 24.08
35 15.07 3.05 0.00 0.00 0.00 18.12
36 40.90 21.81 3.81 0.00 0.00 66.52
37 35.59 10.56 0.00 0.00 0.00 46.15
38 25.03 14.21 0.00 0.00 0.00 39.24
39 22.36 10.42 0.00 0.00 0.00 32.78
40 4.65 0.88 0.00 0.00 0.00 5.53
doi:10.1371/journal.pone.0017282.t002
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were comparable to the RBP4 ELISA from Immun Diagnostik as
shown in the method comparison study and exhibited a low
percentage of bias. Moreover, the performance characteristics
determined for the assay were competitive with standard ELISA
approaches.
The RBP4 MSIA demonstrated in this study is both high
throughput and automated (ideal for large scale clinical applica-
tion), and since the MS analyses are performed on the intact
immuno-affinity captured protein there is no need for time
consuming and costly proteolytic digestion. Not only does the
omission of this step reduce cost, decrease sample complexity and
provide a large time savings over other quantitative proteomic
approaches that are competing for clinical acceptance [18,24], but
allows for the detection, identification and quantification of
endogenous protein variants in a single analysis. Such protein
target heterogeneity is also undetectable by standard ELISA
techniques, giving this approach the unique ability to provide an
added dimension in routine protein analysis that is not easily
performed by other analytical methods.
As a clinical biomarker of insulin resistance and type 2 diabetes
[11], the quantitation of retinol binding protein 4 has gained much
interest in the past few years and has been extensively studied and
associated with a variety pathologies [25,26,27]. However, very
few clinical investigations have ever examined the micro-
heterogeneity of RBP4 in association with a disease state
[13,14,15]. The reason for this is simply because of a lack of
ability to rigorously and reproducibly analyze for such structural
variation; whether in RBP4 or any other protein target. This
alternative approach to clinical proteomics can easily be viewed as
the next generation in ELISA measurements because it provides
the same information as the original, but with the addition of the
novel ability to detect and quantify the micro-heterogeneity that is
also present. Since this assay utilizes a doped exogenous protein for
quantitative reference, its versatility as an internal reference
standard allows for the expedited and economical development
and application of similar dual-function MSIA, but for other
protein targets. Even though there is much hype regarding
alternative bottom-up methods, which prophesize the ability to
perform such variant measurements; to date these approaches
cannot perform such measurements in a single analysis as
demonstrated.
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